Literature DB >> 16642419

Effectiveness of a screening program for hepatitis C.

Ramsey C Cheung1, Barbara A Cunningham, Allen D Cooper.   

Abstract

We sought to determine the outcomes of a screening program for hepatitis C virus (HCV) infection. Of 536 veterans initially screened between July 2000 and June 2001 for risk factors and then tested positive for antibody for HCV, only 260 (48.5%) kept their initial appointments for further evaluation; 51 were not viremic and only 19 (9.1%) were treatment eligible. Of the 276 who did not keep their initial appointments, 92 were subsequently evaluated over the next 2 years and 23 (25%) were treatment eligible, along with another 15 from the first group. Thus, with appropriate intervention and long-term follow-up, there were 57 treatment candidates. In conclusion, most veterans who tested positive either failed to keep their appointment or were ineligible for treatment when first evaluated. Over the following 2 years, some were lost to follow-up, many continued to have contraindication(s) to antiviral therapy, and relatively few were treatment candidates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16642419     DOI: 10.1007/s10620-006-9100-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  12 in total

Review 1.  Cost-effectiveness of combined interferon and ribavirin versus interferon alone.

Authors:  R S Koff
Journal:  Clin Liver Dis       Date:  1999-11       Impact factor: 6.126

Review 2.  EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement.

Authors: 
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

Review 3.  National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

Authors: 
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

4.  Surprisingly small effect of antiviral treatment in patients with hepatitis C.

Authors:  Yngve Falck-Ytter; Hemangi Kale; Kevin D Mullen; Steedman A Sarbah; Lucian Sorescu; Arthur J McCullough
Journal:  Ann Intern Med       Date:  2002-02-19       Impact factor: 25.391

Review 5.  National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C.

Authors: 
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

6.  Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center.

Authors:  M E Briggs; C Baker; R Hall; J M Gaziano; D Gagnon; N Bzowej; T L Wright
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

Review 7.  What is (cost) effective in patients with chronic hepatitis C virus infection?

Authors:  S Zeuzem
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 2.566

8.  Epidemiology of hepatitis C virus infection in American veterans.

Authors:  R C Cheung
Journal:  Am J Gastroenterol       Date:  2000-03       Impact factor: 10.864

9.  A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection.

Authors:  Andrew J Muir; Dawn Provenzale
Journal:  J Clin Gastroenterol       Date:  2002-03       Impact factor: 3.062

10.  Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

Authors:  T Poynard; P Bedossa; P Opolon
Journal:  Lancet       Date:  1997-03-22       Impact factor: 79.321

View more
  6 in total

1.  Correlates of hazardous drinking among Veterans with and without hepatitis C.

Authors:  Megan Oser; Michael Cucciare; John McKellar; Kenneth Weingardt
Journal:  J Behav Med       Date:  2012-01-11

2.  Utilization and antiviral therapy in patients with chronic hepatitis C: analysis of ambulatory care visits in the US.

Authors:  Ramsey Cheung; Ajitha Mannalithara; Gurkirpal Singh
Journal:  Dig Dis Sci       Date:  2010-02-26       Impact factor: 3.199

3.  The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.

Authors:  David B Rein; John S Wittenborn; Bryce D Smith; Danielle K Liffmann; John W Ward
Journal:  Clin Infect Dis       Date:  2015-03-16       Impact factor: 9.079

4.  Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.

Authors:  Bruce R Schackman; Jared A Leff; Devra M Barter; Madeline A DiLorenzo; Daniel J Feaster; Lisa R Metsch; Kenneth A Freedberg; Benjamin P Linas
Journal:  Addiction       Date:  2015-01       Impact factor: 7.256

Review 5.  Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review.

Authors:  Freke R Zuure; Anouk T Urbanus; Miranda W Langendam; Charles W Helsper; Charlotte H S B van den Berg; Udi Davidovich; Maria Prins
Journal:  BMC Public Health       Date:  2014-01-22       Impact factor: 3.295

6.  The hepatitis C cascade of care: identifying priorities to improve clinical outcomes.

Authors:  Benjamin P Linas; Devra M Barter; Jared A Leff; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Arthur Y Kim; Bruce R Schackman
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.